MOTS-c vs SLU-PP-332
Updated 8 sources
Key differences
- 1SLU-PP-332 is a synthetic small molecule acting on ERR nuclear receptors. MOTS-c is a 16-amino-acid peptide made by mitochondria, acting through AMPK.
- 2WADA names MOTS-c on its 2026 List under S4.4. SLU-PP-332 is not named, and at most the catch-all S0 class could apply.
Side by side
Facts from each record, in the same words as their own pages.
| MOTS-c | SLU-PP-332 | |
|---|---|---|
| Category |
|
|
| Evidence |
|
|
| FDA status |
|
|
| WADA |
|
|
| Half-life |
|
|
| Routes |
|
|
| Forms |
|
|
| Reported doses |
|
|
| Most cited frequency |
|
|
| Vial sizes |
|
|
| Mixed vial keeps |
|
|
| Protocols on file |
|
|
Doses shown are what sources report, labelled by origin. Not medical advice.
Read each in full
Sources
8 sources, each checked by date. Record updated Oct 24, 2026. Numbers are restated in our own words and labelled by where they came from.
Clinical study3
- PubMed search: MOTS-c pharmacokinetics or half-lifePubMed · checked Oct 23, 2026
- Billon C et al. 2023, Synthetic ERRα/β/γ agonist induces an ERRα-dependent acute aerobic exercise response and enhances exercise capacity, ACS Chem BiolPMC (NIH) · checked Oct 24, 2026
- Billon C et al. 2024, A synthetic ERR agonist alleviates metabolic syndrome, J Pharmacol Exp TherPMC (NIH) · checked Oct 24, 2026
Regulatory3
- WADA Prohibited List 2026WADA · checked Oct 24, 2026
- FDA briefing document, PCAC July 23 to 24, 2026: MOTS-cFDA · checked Oct 23, 2026
- Interim 503A bulks listFDA · checked Oct 24, 2026
Competitor guide2
- SLU-PP-332 guide: dosing, reconstitution and ERR agonist research referencepeptidedosingprotocols.com · checked Oct 24, 2026
- SLU-PP-332: benefits, dosage, side effects and how the exercise mimetic workspeptidedeck.com · checked Oct 24, 2026